The introduction of a new class of positron emission tomography (PET) radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA), has facilitated the detection of recurrent or metastatic PCa cells that is otherwise occult on conventional imaging [12–15]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.